Abstract:

AIM: To observe the levels of monocyte-platelet aggregates (MPA) and markers of activated monocytes in patients with unstable angina pectoris (UAP) accepting Ginkgo biloba tablet treatments, and to explore its mechanisms for cardiovascular disease treatments. METHODS: The levels of MPA, CD11b, and MCP-1 were measured in 92 unstable angina pectoris (UAP) and 42 stable angina pectoris (SAP). The UAP patients were randomly assigned into routine treatment group (control group) and combined tablet treatment group (Ginkgo biloba group). The efficacy was assessed, and the levels of MPA, CD11b, and MCP-1 were measured after 28 days of treatment, respectively. RESULTS: The levels of MPA, CD11b, and MCP-1 in UAP group were higher than those in SAP group (P<0.001). The levels of MPA and CD11b were positively correlated with MCP-1 level (P<0.01). The total rate of effective Ginkgo biloba tablet treatment was higher than that of non-Ginkgo biloba tablet treatment (P<0.05). After 28 days of treatments, the levels of MPA, CD11b, and MCP-1 in Ginkgo biloba group were significantly lower than those in control group (P<0.001). In total effective treatment group, the levels of MPA, CD11b, and MCP-1 were significantly lower after treatment than those before treatment（P<0.001）, and the decreased rates of these markers after treatment were also much higher (P<0.01). CONCLUSION: There is an obvious efficacy of Ginkgo biloba tablet on unstable angina pectoris by down-regulating the levels of MPA, CD11b and MCP-1.

Key words: Ginkgo biloba tablet, unstable angina pectoris, monocyte-platelet aggregates, CD11b, MCP-1